Navigation Links
CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma
Date:11/3/2008

nically meaningful and important regulatory endpoint. The apparent prolongation in PFS of 4.5 months, compared to a historical expectation of 1.7 months, combined with clear objective responses and tumor reduction in the majority of patients, suggests that CR011-vcMMAE has the potential to become an important novel therapy in this patient population," commented Dr. Timothy Shannon, President and Chief Executive Officer of CuraGen.

As expected based upon the expression of GPNMB and as observed in Phase I, dermatologic adverse events consisting of rash, alopecia, and pruritus were the most common toxicities in this study. A preliminary exploratory analysis assessing the relationship of rash and PFS was performed and showed a trend toward longer PFS in patients that developed Grade 2 or higher rash (n=13). Other adverse events included fatigue, diarrhea, anorexia and nausea. Grade 3 or 4 neutropenia was observed in 7 patients (22%).

"The target of CR011-vcMMAE, GPNMB, is a protein that is believed to be over expressed in a variety of tumors and also present in some normal tissue including the skin. The preliminary data which may suggest a correlation between the development of rash and clinical efficacy is very intriguing and we will continue to assess its potential role in helping to identify those patients who may best respond to treatment with CR011-vcMMAE," commented Dr. Ronit Simantov, Chief Medical Officer at CuraGen. "We would like to thank our investigators for their enthusiasm, which we believe is highlighted by their ability to fully enroll this Phase II trial in just 6 months, and we look forward to reporting the final data from this Phase II trial during the first half of 2009."

"Targeting GPNMB with this antibody-drug conjugate represents a potentially novel way to treat this disease, and based on these preliminary Phase II results, CR011-vcMMAE appears to be clinically active against unresectable melanoma in some patients. We look for
'/>"/>

SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. CuraGen Announces Top-Line Phase II Results on Velafermin
4. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
5. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
6. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
7. CuraGen Advances CR011-vcMMAE into Phase II
8. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
9. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
10. CuraGen Announces Initiation of Phase II Trial of CR011-vcMMAE in Patients with Advanced Breast Cancer
11. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... 04, 2015 Research ... addition of the "MRI Systems Market to ... Efficiency, with Growth Driven by Developing Economies" ... Market to 2020 - Focus on Patient Comfort ... Economies" discusses the market, competitive landscape, and trends ...
(Date:8/4/2015)... and LOS ANGELES , Aug. ... DGX ), the world,s leading provider of diagnostic ... the previously announced acquisition of MemorialCare Health System,s ... a result of the transaction, patients and physicians ... innovative services and network of nearly 200 patient ...
(Date:8/4/2015)... Pharma, Inc. (Nasdaq: MEIP ), an oncology company focused ... today that Daniel P. Gold , Ph.D., President and ... Healthcare Conference on Tuesday, August 11, 2015 at 3:40 p.m. ... New York . A live webcast of the ... will be available approximately one hour after the presentation. ...
Breaking Medicine Technology:Global MRI Systems Market Outlook to 2020 - Focus on Patient Comfort and Operational Efficiency, with Growth Driven by Developing Economies 2Quest Diagnostics Completes Acquisition of MemorialCare Health System's Laboratory Outreach Service Business in Southern California 2MEI Pharma to Present at Wedbush PacGrow Healthcare Conference 2
... Sosei Group Corporation,("Sosei"; TSE Mothers Index: 4565), ... Japanese Phase III clinical trial for the,emergency contraceptive ... rights to the product in Japan from HRA ... evaluate the safety and prevented,pregnancy rate of SOH-075 ...
... Americans, WASHINGTON, July 9 In a congressional,hearing ... the,safety and importance of the research programs operated by ... absolute commitment to its patients,while expressing regret that even ... "VA has an outstanding research program, and has been ...
Cached Medicine Technology:Sosei Announces Completion of Phase III Trial for NorLevo(R) 2Secretary Reinforces VA's Commitment to Research Safety and Veteran Focus 2Secretary Reinforces VA's Commitment to Research Safety and Veteran Focus 3
(Date:8/4/2015)... ... August 04, 2015 , ... How cool is it to check in at ... The new "Now" feature will soon allow you to do just that. , Ahhaa ... other using the now feature. , Users will soon get to share what inspires ...
(Date:8/4/2015)... ... 2015 , ... World Patent Marketing, a vertically integrated manufacturer ... invention that eliminates the need to have a partner or trainer when using ... worth $30 billion," says Scott Cooper, CEO and Creative Director of World Patent ...
(Date:8/4/2015)... WASHINGTON, D.C. (PRWEB) , ... August 04, 2015 ... ... issues fellowship focused on sexual and reproductive health and rights in Indonesia for ... Journalists will visit a number of sites in Indonesia and attend the International ...
(Date:8/4/2015)... CA (PRWEB) , ... August 04, 2015 , ... An ... that found financial incentives to be a viable method for encouraging people to lose ... money on the future of their weight loss success, adding a financial incentive to ...
(Date:8/4/2015)... CA (PRWEB) , ... August 04, 2015 , ... ... are suffering from underarm sweat. Evolutions Medical & Day Spa in Santa Barbara, ... the only non-invasive, FDA cleared treatment that permanently eliminates sweat and odor glands ...
Breaking Medicine News(10 mins):Health News:Ahhaa App Soon to Release the "Now" Feature 2Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 2Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 3Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 4Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 5Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 6Health News:UN Foundation Announces Press Fellowship to Indonesia with Focus on Women’s Health and Rights 2Health News:Article on Incentivizing Weight Loss Mirrors Similar Motivations Surrounding Weight Loss Surgery, Says Dr. Feiz & Associates 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 3
... , , VOORHEES, N.J., Sept. ... involving the skin, visceral organs, and airway, causing discomfort and even ... of therapies available for the prevention and treatment of angioedema, and ... acute attacks on this patient population. , , ...
... Calls on Congress to Enact Reform , ... Liability and Access today commended President Obama for acknowledging the need ... Congress to follow the President,s leadership by including reform in pending ... an address to Congress, President Obama said, "I,ve talked to enough ...
... , , , ... announced today that it has established the Edward Neurosciences Institute ... the highest level of stroke care in the world to ... (Photo: http://www.newscom.com/cgi-bin/prnh/20090910/CG73991 ) , , ...
... , , GREEN ... to keep a strong, healthy immune system. That means getting enough ... there are body stressors you can,t avoid. Environmental toxins are all ... The effects of these toxins can result in a toxic burden ...
... , , NEW BRUNSWICK, ... New York Giants vs. Washington Redskins game this Sunday, September ... new fight: supporting PSE&G Children,s Specialized Hospital, an inpatient rehabilitation ... life-changing conditions. , , Through an ...
... , ... of Cosmetic Injectables Can be a Felony , ... New York, NY (Vocus) September 10, 2009 -- One year in prison ... cosmetic injectables. As recently as August 2009, five physicians, one nurse and a practice ...
Cached Medicine News:Health News:New Directions in Angioedema: A Focus on Supportive Care and Treatment Options 2Health News:Broad Health Coalition Applauds President Obama's Commitment to Medical Liability Reform 2Health News:Edward Announces New Neurosciences Institute in Partnership With Northwestern Medical Faculty Foundation 2Health News:Edward Announces New Neurosciences Institute in Partnership With Northwestern Medical Faculty Foundation 3Health News:The #1 Stay Healthy Secret - Whole Body Cleanse(TM) from Enzymatic Therapy 2Health News:PSE&G Children's Specialized Hospital and New York Giants Team Up to Offer Text to Donate Campaign 2Health News:Physicians Coalition for Injectable Safety Urges Reporting of Suspected Illegal Solicitation or Use of Botox, Restylane, Radiesse and Others 2Health News:Physicians Coalition for Injectable Safety Urges Reporting of Suspected Illegal Solicitation or Use of Botox, Restylane, Radiesse and Others 3
A simple solution to hand assisted laparoscopic surgery....
... The HandPort Systems non-adhesive ... during Hand-Assisted Laparoscopic Surgrery (HALS) ... touch, grasp, and palpate throughout. ... small as 6 cm, patients ...
... 200 series offers a range of ... The design delivers therapy to meet ... promote results in commercial and clinical ... differentiator in the SleepStyle 200 series ...
The SleepStyle 600 series with ThermoSmart delivers humidification with anti-rainout benefits. ThermoSmart technology offers a heated breathing tube that allows the constant delivery of optimal level...
Medicine Products: